Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,166.00
Bid: 1,160.00
Ask: 1,166.00
Change: 0.00 (0.00%)
Spread: 6.00 (0.517%)
Open: 1,192.00
High: 1,192.00
Low: 1,160.00
Prev. Close: 1,166.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update

7 Apr 2009 07:00

RNS Number : 2357Q
Victrex PLC
07 April 2009
 



Tuesday 7 April 2009

Victrex plc

Half Year Trading Update

Victrex will announce its results for the six months ended 31 March 200on Tuesday 19 May 2009. Today, the Company announces its regular half year trading update. 

At our AGM in February, we announced the strategic reorganisation of our business into two divisions: Invibio®, our biomaterials business and Victrex PEEK, now known as Victrex Polymer Solutions. Our half year results will reflect this divisional split.

Overall, we have continued to see strong progress in Invibio, offset by lower volumes in Victrex Polymer Solutions as demand in our major industrial markets has remained weak.

Invibio

Invibio had an excellent first half with revenue of approximately £17.6m, an increase of 50% over the previous first half (£11.7m). We expect second half revenue to be maintained at broadly similar level to the strong first half. 

 

Group sales volume

At approximately 774 tonnes, overall first half sales volume was 40% down on the previous first half as a result of the expected reduction in demand for Victrex PEEK in our major end user industrial markets, particularly automotive and electronics. Across regions, the United States held up better than Europe and the Asia-Pacific markets. 

While February sales volume (at 109 tonnes) was similar to levels experienced in recent monthsMarch (at approximately 90 tonnes) saw evidence of renewed destocking as some customers reduced inventories at the quarter end. 

While it is still too early to make predictions about second half sales volume, current month order levels are running at a higher level than at the same time in March.

For planning purposes, we have assumed that volumes will remain at similar levels to the second quarter and have taken actions to streamline Victrex Polymer Solutions while continuing to invest in new applications and growth areas. We have reduced polymer production levels and are also temporarily suspending BDF monomer production for a period of up to six months.

Average selling price and currency impact

As a result of the reduction in sales volume, we have had to buy out surplus forward exchange contracts that were entered into (prior to the downturn) in compliance with our currency hedging policyAlthough this has a negative impact on effective sterling average selling price, we are also experiencing a positive impact largely driven by the sales mix effect between Invibio and Victrex Polymer Solutions. Accordingly, we still expect to see a significant increase in Group effective sterling average selling price compared to 2008. 

 

Outlook

Our Invibio Biomaterials Solutions division continues to show strong sales growth and development potential. While the Victrex Polymer Solutions division is affected by the global slowdown in our major markets, we remain focussed on developing the underlying growth potential which will be realised when the trading environment improves.

-Ends-

For further information please contact:

Victrex plc

Michael PeacockFinance Director

01253 897700

Hogarth Partnership Limited

Nick Denton / Barnaby Fry

0207 357 9477

  

Victrex plc is an innovative, world leader in high performance materials through the manufacture of VICTREX® PEEK polymer, a high performance, easy to process thermoplastic.

VICTREX PEEK has a unique combination of chemical, wear, electrical, hydrolysis and temperature resistance, as well as excellent dimensional, mechanical and chemical stability combined with inherent purity and low flammability.

End users specify VICTREX PEEK to reduce systems costs, improve part performance, exploit greater design freedom and create a differentiated application. VICTREX PEEK is used across a broad range of applications in diverse markets including transport, industrial, electronics and medical. 

Invibio®, Victrex's biomaterials business, provides specialised solutions for medical device manufacturers.

The Group's headquarters are in the UK where its manufacturing facilities are based. This is complemented by a global network of sales, distribution and technical centres that serve more than 30 countries worldwide.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQQLFBKZBEBBX
Date   Source Headline
14th Jun 20249:00 amRNSAdditional Listing
3rd Jun 20242:19 pmRNSBlock listing Interim Review
3rd Jun 20249:30 amRNSDirector/PDMR Shareholding
31st May 202411:23 amRNSTotal Voting Rights
23rd May 20247:00 amRNSSBTI approval of carbon reduction targets
15th May 20243:59 pmRNSDirector/PDMR Shareholding
14th May 20244:05 pmRNSDirector/PDMR Shareholding
13th May 20247:00 amRNSVictrex plc - Interim Results 2024
7th May 20243:25 pmRNSDirector Declaration
30th Apr 20242:54 pmRNSTotal Voting Rights
28th Mar 20249:56 amRNSTotal Voting Rights
15th Mar 20248:30 amRNSDirectorate Change
6th Mar 20242:06 pmRNSDirector/PDMR Shareholding
29th Feb 20249:36 amRNSTotal Voting Rights
21st Feb 20248:00 amRNSBlock listing Interim Review
9th Feb 202412:16 pmRNSResult of AGM
9th Feb 20247:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202412:26 pmRNSTotal Voting Rights
25th Jan 202410:57 amRNSHolding(s) in Company
9th Jan 202412:13 pmRNSAnnual Report & Accounts
29th Dec 20239:00 amRNSTotal Voting Rights
12th Dec 202310:21 amRNSDirector/PDMR Shareholding
5th Dec 20232:42 pmRNSDirector/PDMR Shareholding
5th Dec 20232:33 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSVictrex plc - Preliminary Results 2023
1st Dec 202310:41 amRNSBlock listing Interim Review
30th Nov 202311:10 amRNSTotal Voting Rights
3rd Nov 20231:31 pmRNSHolding(s) in Company
31st Oct 20239:36 amRNSTotal Voting Rights
19th Sep 20231:59 pmRNSDirector/PDMR Shareholding
8th Sep 20239:32 amRNSHolding(s) in Company
31st Aug 20239:30 amRNSTotal Voting Rights
23rd Aug 202310:52 amRNSHolding(s) in Company
17th Aug 20231:27 pmRNSDirector/PDMR Shareholding
31st Jul 20239:39 amRNSTotal Voting Rights
18th Jul 202311:51 amRNSDirector/PDMR Shareholding
13th Jul 20232:00 pmRNSAdditional Listing
6th Jul 20237:00 amRNSVictrex plc - Q3 Interim Management Statement
3rd Jul 20234:03 pmRNSHolding(s) in Company
30th Jun 20239:37 amRNSTotal Voting Rights
27th Jun 202310:08 amRNSDirector/PDMR Shareholding
19th Jun 20232:27 pmRNSDirector/PDMR Shareholding
14th Jun 20237:00 amRNSTrading Statement
1st Jun 202312:08 pmRNSBlock listing Interim Review
31st May 20239:52 amRNSTotal Voting Rights
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
10th May 20231:34 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.